Genomics and Hemophilia Europe | Lifesciences Review

About Us

Conference

Partner With Us

Syngensys: Transforming Patient Care with Synthetic Biology

CXO INSIGHTS

A Marketer's Guide to Strategically Promoting Oncology Innovation

Jaime Manzanera Gómez, Brand Director of Oncology, Eisai EMEA

Adopting Blockchain Technology for Clinical Trial Management

Tomaz Vaupotic, Senior Director, Head of Clinical & Medical Quality, Alvotech [NASDAQ: ALVO]

Holistic Compliance in Healthcare Organizations

Zina Safer, Chief Legal & Sustainability Officer, Uriach

Establishing A Biotech Company In Europe: A Mission Impossible?

Rüdiger Schulze, Vice President and General Manager, DACH, Ultragenyx

Early Phase Biologics Characterization; a Key Factor for Risks Mitigation in Biologics Product Developments

Rafael Sande, Head Operations Characterization Large Molecule / Cell- and Gene Therapy Services at Solvias AG

Grappling with unpredictability: the art and science of pandemic preparedness

Marc Lacey, Global Pandemic Head for Seqirus

COVER STORY

Syngensys: Transforming Patient Care with Synthetic Biology

Professor David James, Chief Scientific Officer, Syngensys

Company Of the year

BIOVIIIx: Championing Patient-Centric Innovations in Haemophilia Treatment

Davide Rosiello, CEO, BIOVIIIx

IN MY OPINION

The Tipping Point for Scalable Manufacturing Processes to Pivot Gene Therapies

Dr Linda Randall, AVP Biologics Development, Manufacturing & Control, Pharmaron

In Focus

CRISPR's Promise for Hemophilia Patients

The Role of Genomics in Evolutionary Medicine

LAST WORD

A proposal for a new strategy in oncology clinical development

Stefano Ferrara, Director, Clinical Science, BeiGene

Specials